ARCH Venture Partners raised its largest venture capital fund yet, the $1.85bn ARCH Venture Fund XI, which it plans to invest in a range of biotechnology opportunities, including drug developers focused on infectious disease, mental health, immunology, oncology and neurology.
The VC firm, which closed two funds totaling $1.1bn in April, said on 28 January that it will also invest...






